Table 1 Baseline characteristics of enrolled participants
Variable | Artemether–lumefantrine + efavirenz-based ART (N = 152) |
|---|---|
Age in years, median (IQR) | 40.4 (34–46.1) |
Female (%) | 101 (66.5) |
Body mass index, kg/sq m, median (IQR) | 19.5 (18.3–21.4) |
WHO BMI classification, n (%) | |
Underweight (< 18.5) | 45 (29.6) |
Normal (18.5–24.9) | 99 (65.1) |
Overweight (25.0–29.9) | 5 (3.3) |
Obese (> 30) | 3 (2.0) |
Duration on ART in months, median (IQR) | 24 (10.5–48) |
Presenting symptoms, n (%) | |
Fever | 124 (81.6) |
Headache | 119 (78.3) |
Fatigue | 47 (30.9) |
Nausea | 14 (9.2) |
Axillary temperature at enrolment, median (IQR) | 36.4 (36.0–36.7) |
Febrile, n (%) | 12 (7.9) |
Geometric mean parasite density, 95% CI | 1108 (841–1463) |
Parasite density > 2000 parasites/µL, n (%) | 53 (34.9) |
Parasite density > 10,000 parasites/µL, n (%) | 19 (12.5) |
Pre-treatment haemoglobin concentration, g/dL, median (IQR) | 11.3 (10.5–12.4) |
Pre-treatment CD4 cell count, median (IQR) | 376 (248–511) |
CD4 cell count < 350, n (%) | 67 (44.1) |
Median (IQR) QTcF interval (ms) | 393 (358–413) |
Current use of cotrimoxazole prophylaxis, % (n) | 53 (34.9) |